Pulmonary cytomegalovirus infection in immunocompromised patients.
BACKGROUND
Cytomegalovirus (CMV) infection and CMV disease are frequent complications in immunocompromised patients. In this study, the incidence of pulmonary CMV infection was analyzed in different groups of immunocompromised patients and the diagnostic value of immunostaining with anti-CMV antibodies in BAL cells was evaluated in regard to the diagnosis of CMV pneumonitis.


METHODS
Five hundred eighty consecutive BAL procedures were analyzed prospectively in 442 immunocompromised and 126 nonimmunocompromised control subjects. CMV culture in BAL fluid was performed by shell vial assay and immunostaining using three monoclonal anti-CMV antibodies.


RESULTS
The incidence of culture results positive for CMV in the BAL fluid varied from 20 to 30% in HIV-positive patients, in patients following stem cell or renal transplantation, and in patients with autoimmune disease or lung fibrosis treated with immunosuppressive agents. CMV was cultured from 4.4% of BALs in patients treated with high-dose chemotherapy and from 2.4% of control subjects. CMV disease developed in 37 patients; in 18 of these patients, CMV pneumonitis was present. The results of CMV immunostaining were positive in a total of 22 BALs, all in patients with CMV disease. The sensitivity, specificity, and positive and negative predictive values of positive CMV immunostaining results for the diagnosis of CMV pneumonitis were 88.9%, 98.6%, 72.7%, and 99.5%, respectively.


CONCLUSIONS
The incidence of pulmonary CMV infection is similar in different groups of immunocompromised patients except for patients following high-dose chemotherapy. CMV immunostaining in the BAL fluid is a very helpful method to diagnose CMV pneumonitis in these patients.
Tamm
M
M
Division of Pneumology, Department of Internal Medicine, University Hospital Basel, Basel, Switzerland. mtamm@uhbs.ch
Traenkle
P
P
Grilli
B
B
Solèr
M
M
Bolliger
C T
CT
Dalquen
P
P
Cathomas
G
G
D000914:Antibodies, Viral / Q000032:analysis; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology / Q000821:virology*; D016022:Case-Control Studies; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology*; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D011024:Pneumonia, Viral / Q000175:diagnosis / Q000453:epidemiology / Q000276:immunology* / Q000821:virology; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity
D000914:Antibodies, Viral